![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Switch from efavirenz/emtricitabine/tenofovir DF to elvitegravir/cobicistat/emtricitabine/tenofovir DF: Efficacy and Pharmacokinetics
|
|
|
Reported by Jules Levin
ICAAC 2013 Denver Colorado Sept 10-13
C Cohen1, R Elion2, P Ruane3, D Shamblaw4, E DeJesus5, B Rashbaum6, J Custodio7, S Ramanathan7, M Fordyce7, MS Rhee7, B Kearney7, J Szwarcberg7
1Community Research Initiative, Boston, MA, US; 2Whitman Walker Clinic, Washington, DC, US; 3Peter J. Ruane, MD, Inc., Los Angeles, CA, US; 4La Playa Medical Group and Clinical Research, San Diego, CA, US;
5Orlando Immunology Center, Orlando, FL, US; 6Capital Medical Associates PC, Washington, DC, US; 7Gilead Sciences, Foster City, CA, US
![ICAAC1.gif](../images/091213/091213-4/ICAAC1.gif)
![ICAAC2.gif](../images/091213/091213-4/ICAAC2.gif)
![ICAAC3.gif](../images/091213/091213-4/ICAAC3.gif)
![ICAAC4.gif](../images/091213/091213-4/ICAAC4.gif)
![ICAAC5.gif](../images/091213/091213-4/ICAAC5.gif)
![ICAAC6.gif](../images/091213/091213-4/ICAAC6.gif)
![ICAAC7.gif](../images/091213/091213-4/ICAAC7.gif)
![ICAAC8.gif](../images/091213/091213-4/ICAAC8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|